H19 and hepatoblastoma: The GOM at the H19/IGF2:IG DMR (IC1) is associated with childhood cancer in 28% of cases (nephroblastoma 24%) and a upd(11)pat has a cumulative childhood tumor risk of approximately 16% (nephroblastoma > hepatoblastoma > neuroblastoma), whereas with a KCNQ1OT1:TSS DMR hypomethylation (IC2 LOM) up to 2.5% of patients develop a tumor (0.7% hepatoblastoma).